CA3075729A1 - Utilisation d'oleandrine pour traiter une infection virale - Google Patents

Utilisation d'oleandrine pour traiter une infection virale Download PDF

Info

Publication number
CA3075729A1
CA3075729A1 CA3075729A CA3075729A CA3075729A1 CA 3075729 A1 CA3075729 A1 CA 3075729A1 CA 3075729 A CA3075729 A CA 3075729A CA 3075729 A CA3075729 A CA 3075729A CA 3075729 A1 CA3075729 A1 CA 3075729A1
Authority
CA
Canada
Prior art keywords
infection
subject
acid
antiviral composition
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3075729A
Other languages
English (en)
Inventor
Robert A. Newman
Otis C. Addington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phoenix Biotechnology Inc
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/051553 external-priority patent/WO2018053123A1/fr
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of CA3075729A1 publication Critical patent/CA3075729A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Une utilisation d'une composition antivirale contenant de l'oléandrine est décrite pour traiter une infection virale causée par le virus Ebola, le virus de Marburg, l'encéphalite japonaise, le virus Zika, le virus de l'encéphalite équine du Vénézuela, le virus de l'encéphalite équine de l'Ouest, le virus de l'encéphalite équine de l'Est et le virus Nipah. La composition peut aussi comprendre au moins un triterpène.
CA3075729A 2017-09-14 2018-07-16 Utilisation d'oleandrine pour traiter une infection virale Pending CA3075729A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
USPCT/US2017/051553 2017-09-14
PCT/US2017/051553 WO2018053123A1 (fr) 2016-09-14 2017-09-14 Méthodes et compositions de traitement d'infections virales
US201862698365P 2018-07-16 2018-07-16
PCT/US2018/042226 WO2019055119A1 (fr) 2017-09-14 2018-07-16 Méthode et composition pour le traitement d'une infection virale
US62/698,365 2018-07-16

Publications (1)

Publication Number Publication Date
CA3075729A1 true CA3075729A1 (fr) 2019-03-21

Family

ID=65723839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3075729A Pending CA3075729A1 (fr) 2017-09-14 2018-07-16 Utilisation d'oleandrine pour traiter une infection virale

Country Status (9)

Country Link
EP (1) EP3681508A4 (fr)
JP (3) JP6820450B2 (fr)
KR (2) KR102295179B1 (fr)
AU (2) AU2018334386B2 (fr)
CA (1) CA3075729A1 (fr)
IL (2) IL285232B (fr)
MX (1) MX2020002883A (fr)
RU (1) RU2020113341A (fr)
WO (1) WO2019055119A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220151038A (ko) 2020-03-31 2022-11-11 피닉스 바이오테크놀러지 인코포레이티드. 코로나바이러스 감염 예방를 위한 조성물
ES2965161T3 (es) * 2020-03-31 2024-04-11 Phoenix Biotechnology Inc Método y composiciones para el tratamiento de infección por coronavirus
EP4295854A3 (fr) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Méthode et compositions pour le traitement d'une infection à coronavirus
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
FR3109297A1 (fr) * 2020-04-19 2021-10-22 Ephyla « Nouvel inhibiteur non protéique de furine »
WO2022094816A1 (fr) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Formulation solide
US12465645B2 (en) * 2022-04-01 2025-11-11 Alexia Reif Anti-viral composition and method for preparing the same
KR102704483B1 (ko) * 2023-02-28 2024-09-10 대한민국(질병관리청 국립보건연구원장) 스테로이드 유도체 계열 화합물 및 이를 유효성분으로 함유하는 항바이러스제

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK239687A (da) 1986-05-13 1987-11-14 Huseyin Ziya Ozel Planteekstrakter
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
CA2191923C (fr) 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea et croissance des cellules tumorales
CA2330916C (fr) 1998-05-19 2011-04-05 Research Development Foundation Compositions de triterpene et leurs champ d'application
US6565897B2 (en) 1998-09-24 2003-05-20 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
AU8494601A (en) 2000-08-18 2002-03-04 Univ Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV
US9931316B2 (en) * 2004-01-06 2018-04-03 Paul Edward Stamets Antiviral activity from medicinal mushrooms and their active constituents
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
DE60204078T2 (de) 2001-04-09 2006-01-26 Loders Croklaan B.V. Konzentrat von Triterpenen
EP2567625A1 (fr) 2001-05-11 2013-03-13 University Of Ottawa Préparation à base d'acide bétulinique obtenue à partir d'une plante de la famille des Marcgraviaceae
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
WO2003099011A1 (fr) * 2002-05-28 2003-12-04 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Utilisation de glucosides cardiotoniques pour le traitement de la mucovicidose et autres troubles dependant de il-8
EP1585504A4 (fr) 2002-11-06 2009-07-15 Azaya Therapeutics Inc Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines
WO2004087121A2 (fr) 2003-03-28 2004-10-14 Azaya Therapeutics, Inc. Formulations hydrosolubles de glycoside digitaux en vue du traitement de la proliferation cellulaire et d'autres maladies
BRPI0508854A (pt) 2004-03-17 2007-08-28 Panacos Pharmaceuticals Inc sais farmacêuticos de ácido-3-o-(3',3'-dimetilsuccinil) betulìnico
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
WO2006085334A2 (fr) 2005-02-09 2006-08-17 Dabur Pharma Limited Nouveaux derives d'acide betulinique
AU2006230429A1 (en) 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing TEMPO
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
US20090131714A1 (en) 2005-06-08 2009-05-21 Krasutsky Pavel A Synthesis of betulonic and betulinic aldehydes
JP5080249B2 (ja) 2005-06-10 2012-11-21 ポーラ化成工業株式会社 新規トリテルペン酸誘導体及びそれを含有してなる皮膚外用剤
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CN101374527A (zh) 2005-12-16 2009-02-25 帕纳克斯医药公司 3-o-(3’,3’-二甲基琥珀酰基)桦木酸的药物盐的制备方法
EP1803461A1 (fr) * 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Utilisation therapeutique d'un extrait de feuilles de Nerium oleander
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
WO2008063318A2 (fr) 2006-10-12 2008-05-29 The Texas A & M University System And Safe Et Al Acide bétulinique, dérivés et analogues de celui-ci, et leurs utilisations
CA2668452A1 (fr) 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Derives de triterpene etendus
WO2008091532A1 (fr) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Sels de l'acide 3-o-(3',3'-diméthylsuccinyl)bétulinique et leurs formes à l'état solide
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
CA2705272C (fr) 2007-11-13 2020-05-12 Phoenix Biotechnology Inc. Procede de determination de la probabilite d'une reponse therapeutique dans la chimiotherapie anticancereuse avec un glycoside cardiaque
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
US20110224159A1 (en) 2008-09-10 2011-09-15 Universite du Quebec a Chicoutime Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
WO2010053817A1 (fr) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Dérivés de l’acide bétulinique et leurs méthodes d’utilisation
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
CN101704872B (zh) 2009-11-23 2012-06-27 张南 23-羟基白桦酸衍生物、其制备方法及应用
US8685469B2 (en) 2009-11-30 2014-04-01 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
KR101811462B1 (ko) 2010-01-11 2018-01-25 피닉스 바이오테크놀러지 인코포레이티드. 협죽도 추출물을 포함하는 신경질환 치료용 조성물
TWI386415B (zh) 2010-02-02 2013-02-21 Univ Kaohsiung Medical 熊果酸衍生物及其醫藥組合物
TWI410431B (zh) 2010-12-22 2013-10-01 Ind Tech Res Inst 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
US20140221328A1 (en) 2011-01-10 2014-08-07 Bandi Parthasaradhi Reddy Pharmaceutically acceptable salts of novel betulinic acid derivatives
HUE026371T2 (en) 2011-01-31 2016-05-30 Bristol Myers Squibb Co C-28 amines from modified C-3 betulinic acid derivatives as anti-HIV matrices
CN102558280B (zh) 2011-11-18 2014-09-17 温州大学 一种30-卤代桦木酸的生产方法
JP6211527B2 (ja) 2011-12-01 2017-10-11 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ２−置換オレアノール酸誘導体、その調製方法及びその用途
CN103946231B (zh) 2011-12-01 2016-10-26 杭州本生药业有限公司 齐墩果酸酰胺化衍生物、及其制备方法和应用
WO2013160810A2 (fr) 2012-04-24 2013-10-31 Hetero Research Foundation Nouveaux dérivés d'acide bétulinique à titre d'inhibiteurs du vih
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2014027777A2 (fr) 2012-08-14 2014-02-20 한국콜마 주식회사 Nouveau dérivé d'acide ursolique et son procédé de préparation
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
SMT201700501T1 (it) 2012-09-10 2017-11-15 Reata Pharmaceuticals Inc Derivati c17-eteroarilici dell'acido oleanolico e metodi d'uso degli stessi
WO2014040073A1 (fr) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. Dérivés c13-hydroxy de l'acide oléanolique et leurs procédés d'utilisation
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
KR20150121712A (ko) 2013-02-25 2015-10-29 브리스톨-마이어스 스큅 컴퍼니 Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체
EP3105241A1 (fr) * 2014-02-12 2016-12-21 Organo Balance GmbH Souche de levure et procédé microbien de production de triterpènes et/ou triterpénoïdes pentacycliques
WO2015195776A1 (fr) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Dérivés d'acide bétulinique présentant une activité inhibitrice de maturation du vih
US9492438B2 (en) * 2014-07-25 2016-11-15 Bette Pollard Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system
WO2016200672A1 (fr) * 2015-06-08 2016-12-15 Cutanea Life Sciences, Inc. Composition thérapeutique

Also Published As

Publication number Publication date
JP2021063105A (ja) 2021-04-22
KR102295179B1 (ko) 2021-08-30
IL285232A (en) 2021-09-30
RU2020113341A3 (fr) 2021-10-15
AU2018334386B2 (en) 2021-11-04
IL285232B (en) 2022-07-01
EP3681508A4 (fr) 2021-05-19
MX2020002883A (es) 2020-10-05
JP7037673B2 (ja) 2022-03-16
WO2019055119A1 (fr) 2019-03-21
JP6820450B2 (ja) 2021-01-27
AU2020204236B2 (en) 2020-12-10
IL273162B (en) 2021-08-31
JP2020534293A (ja) 2020-11-26
IL273162A (en) 2020-04-30
EP3681508A1 (fr) 2020-07-22
KR20200081356A (ko) 2020-07-07
JP2022075755A (ja) 2022-05-18
RU2020113341A (ru) 2021-10-15
AU2018334386A1 (en) 2020-04-02
KR20210107904A (ko) 2021-09-01
AU2020204236A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
EP3512524B1 (fr) Méthodes et compositions de traitement d'infections virales
US10596186B2 (en) Method and compositions for treating viral infections
AU2020204236B2 (en) Method and composition for treating viral infection
US11324789B2 (en) Method and compositions for treating equine encephalitis
IL291727B2 (en) Method and preparations for treating the corona virus infection
US20220047616A1 (en) Method and Compositions for Treating HTLV-1 Virus Infection
HK40012419B (en) Method and compositions for treating viral infection
HK40012419A (en) Method and compositions for treating viral infection
HK40021211B (en) Method and composition for treating viral infection
HK40021211A (en) Method and composition for treating viral infection
CA3091376A1 (fr) Procede et compositions pour traiter l'infection au coronavirus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220323